Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 March 2020 | Story Amanda Tongha and Andre Damons | Photo Johan Roux
 UFS postgraduate welcoming
Attending the Postgraduate Welcoming were, from the left: Itumeleng Mutla, second-year master’s student; Prof Corli Witthuhn, Vice-Rector: Research, Innovation and Internationalisation; Prof Witness Mudzi, Director of the Postgraduate School; Hesma van Tonder, Chief Officer: Research Librarian; and John van Niekerk, a master’s student.

The University of the Free State prides itself on being an institution committed to excellence in postgraduate education. In 2019, the UFS boasted more than 6 900 postgraduate students enrolled for postgraduate diplomas, honours, master’s and doctoral qualifications. Of these, 77% previously enrolled at the UFS, while 23% started at the institution for the first time.

Targeting this group of students who make up 17% of the total number of degree-seeking students, the UFS Postgraduate School formally welcomed new senior students to the university on Friday 6 March. 

Postgraduate success
“It is the best time to be a senior student, and I hope it is a wonderful experience,” said Prof Corli Witthuhn, Vice-Rector: Research, Innovation and Internationalisation in her welcoming address to the more than 150 postgraduate students gathered in the Reitz Hall of the Centenary Complex. 

Giving reasons as to why Kovsie students should consider postgraduate studies, Prof Witthuhn said there are many opportunities associated with making the jump from undergraduate to postgraduate student.  

“All the data shows that postgraduate studies increase employability. It creates the opportunity to deeper engage with the field that you are interested in.”
 
The postgraduate journey 
D
r Musawenkosi Saurombe, Senior Lecturer in the Department of Industrial Psychology who became the youngest PhD holder on the African continent at age 23, was also on hand to offer advice. 

“Are you willing to see the task to completion? How badly do you want it?” she challenged postgraduate students, talking about her journey from 16-year old first-year student to 23-year-old doctoral degree holder. 

Itumeleng Mutla, who is in the second year of her master’s degree in Administration, said she found the speech by Dr Saurombe inspiring and encouraging. “I felt like a groupie and took pictures with her afterwards. We felt inspired by her story and she encouraged me in my own studies. I think I am also going to push to finish my studies earlier,” she said.

John van Niekerk, a master’s student in Education and Psychology, said Saurombe’s talk was brilliant and he would like her to give a talk to learners at Kimberley Boys High, where he is a teacher. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept